Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ERα-positive breast cancer cells

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.
   Google Scholar
• Fucito A, Lucchetti C, Giordano A, et al. Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice? Int J Biochem Cell Biol. 2008;40(4):565–575.
   Google Scholar
• Tan L, Shi YG. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development. 2012;139(11):1895–1902.
   Google Scholar
• Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118(17):4509–4518.
   Google Scholar
• Yang H, Liu Y, Bai F, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 2013;32(5):663–669.
   Google Scholar
• Yang L, Yu SJ, Hong Q, et al. Reduced expression of TET1, TET2, TET3 and TDG mRNAs are associated with poor prognosis of patients with early breast cancer. PLoS One. 2015;10(7):e0133896.
   Google Scholar
• Tsai KW, Li GC, Chen CH, et al. Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor in breast cancer patients, especially for an ER/PR-negative subtype. Breast Cancer Res Treat. 2015;153(1):219–234.
   Google Scholar
• Wu MZ, Chen SF, Nieh S, et al. Hypoxia drives breast tumor malignancy through a TET-TNFalpha-p38-MAPK signaling Axis. Cancer Res. 2015;75(18):3912–3924.
   Google Scholar
• Hsu CH, Peng KL, Kang ML, et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2012;2(3):568–579.
   Google Scholar
• Sun, Miao, et al. “HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis.” Proceedings of the National Academy of Sciences 110.24 (2013): 9920–9925
   Google Scholar
• Chen JY, Luo CW, Lai YS, et al. Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer. Oncogenesis. 2017;6(8):e369.
   Google Scholar
• Song SJ, Poliseno L, Song MS, et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell. 2013;154(2):311–324.
   Google Scholar
• Wu MJ, Kim MR, Chen YS, et al. Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKCzeta pathway. Oncogene. 2017;36(22):3193–3206.
   Google Scholar
• Good CR, Panjarian S, Kelly AD, et al. TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer. Cancer Res. 2018;78(15):4126–4137.
   Google Scholar
• Collignon E, Canale A, Al Wardi C, et al. Immunity drives TET1 regulation in cancer through NF-κB. Sci Adv. 2018;4(6): eaap7309.
   Google Scholar
• Wang L, Ozark PA, Smith ER, et al. TET2 coactivates gene expression through demethylation of enhancers. Sci Adv. 2018;4(11):eaau6986.
   Google Scholar
• Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013;10(10):957–963.
   Google Scholar
• Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823–826.
   Google Scholar
• Kong L, Tan L, Lv R, et al. A primary role of TET proteins in establishment and maintenance of De Novo bivalency at CpG islands. Nucleic Acids Res. 2016;44(18):8682–8692.
   Google Scholar
• Zhu J, Sammons Ma, Donahue G, et al. Prevalent p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015;525(7568):206–211.
   Google Scholar
• Tan L, Xiong L, Xu W, et al. Genome-wide comparison of DNA hydroxymethylation in mouse embryonic stem cells and neural progenitor cells by a new comparative hMeDIP-seq method. Nucleic Acids Res. 2013;41(7):e84.
   Google Scholar
• Hawkins RD, Hon GC, Ren B. Next-generation genomics: an integrative approach. Nat Rev Genet. 2010;11(7):476–486.
   Google Scholar
• Heintzman ND, Stuart RK, Hon G, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007;39(3):311–318.
   Google Scholar
• Thomas-Chollier M, Hufton A, Heinig M, et al. Transcription factor binding predictions using TRAP for the analysis of ChIP-seq data and regulatory SNPs. Nat Protoc. 2011;6(12):1860–1869.
   Google Scholar
• Qin Q, Fan J, Zheng R, et al. Lisa: inferring transcriptional regulators through integrative modeling of public chromatin accessibility and ChIP-seq data. Genome Biol. 2020;21(1). DOI:10.1186/s13059-020-1934-6
   Google Scholar
• Győrffy B. , Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101–4109.
   Google Scholar
• Grimm SA, Shimbo T, Takaku M, et al. DNA methylation in mice is influenced by genetics as well as sex and life experience. Nat Commun. 2019;10(1):1–13.
   Google Scholar
• Zhang Q, Zhao K, Shen Q, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress Il-6. Nature. 2015;525(7569):389–393.
   Google Scholar
• Wu M-Z, Chen S-F, Nieh S, et al. Hypoxia drives breast tumor malignancy through a TET–TNFα–p38–MAPK signaling axis. Cancer Res. 2015;75(18):3912–3924.
   Google Scholar
• Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839–843.
   Google Scholar
• He YF, Li BZ, Li Z, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011;333(6047):1303–1307.
   Google Scholar
• Lopez-Moyado IF, Tsagaratou A, Yuita H, et al. Paradoxical association of TET loss of function with genome-wide DNA hypomethylation. Proc Natl Acad Sci U S A. 2019;116(34):16933–16942.
   Google Scholar
• Futscher BW. Epigenetic changes during cell transformation. Adv Exp Med Biol. 2013;754:179–194.
   Google Scholar
• Yu M, Hon GC, Szulwach KE, et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell. 2012;149(6):1368–1380.
   Google Scholar
• Hon GC, Song CX, Du T, et al. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol Cell. 2014;56:286–297.
   Google Scholar
• Lu F, Liu Y, Jiang L, et al. Role of Tet proteins in enhancer activity and telomere elongation. Genes Dev. 2014;28(19):2103–2119.
   Google Scholar
• Yamazaki J, Jelinek J, Lu Y, et al. TET2 mutations affect non-CpG Island DNA Methylation at enhancers and transcription factor–binding sites in chronic myelomonocytic Leukemia. Cancer Res. 2015;75(14):2833–2843.
   Google Scholar
• Rasmussen KD, Jia G, Johansen JV, et al. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev. 2015;29(9):910–922.
   Google Scholar
• Zhang P, Rausch C, Hastert FD, et al. Methyl-CpG binding domain protein 1 regulates localization and activity of Tet1 in a CXXC3 domain-dependent manner. Nucleic Acids Res. 2017;45(12):7118–7136.
   Google Scholar
• Ko M, An J, Bandukwala HS, et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature. 2013;497(7447):122–126.
   Google Scholar
• Wang Y, Xiao M, Chen X, et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell. 2015;57(4):662–673.
   Google Scholar
• Carroll JS, Liu XS, Brodsky AS, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005;122(1):33–43.
   Google Scholar
• Theodorou V, Stark R, Menon S, et al. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 2013;23(1):12–22.
   Google Scholar
• Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007;39(5):655–660.
   Google Scholar
• Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–1273.
   Google Scholar
• Iwase H, Yamamoto Y. Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer. Int J Clin Oncol. 2015;20(2):253–261.
   Google Scholar
• Patel HK, Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 2018;186:1–24.
   Google Scholar
• Magnani L, Ballantyne EB, Zhang X, et al. PBX1 genomic pioneer function drives ERalpha signaling underlying progression in breast cancer. PLoS Genet. 2011;7(11):e1002368.
   Google Scholar
• Lupien M, Meyer CA, Bailey ST, et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev. 2010;24(19):2219–2227.
   Google Scholar